TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04487080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Participants will receive amivantamab intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Participants will receive osimertinib capsules orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Participants will receive lazertinib tablets orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Participants will receive lazertinib tablets orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo orally.
Study: NCT02719223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICaS
Description: The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICaS
Description: The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).
Study: NCT02332707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
Study: NCT02608632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation guided by HFS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renal denervation as standard procedure
Study: NCT02332707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
Study: NCT06365762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDTA Ophthalmic Solution 2.6%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDTA Ophthalmic Solution 1.3%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution (Placebo)
Study: NCT03935568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-AD
Description: 3 cohorts receiving a single oral dose of PU-AD at one time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 3 cohorts receiving a single oral dose of Placebo at one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 cohorts receiving multiple oral dose of Placebo at one time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-AD
Description: 2 cohorts receiving multiple oral dose of PU-AD at one time
Study: NCT02828670

Intervention type: BIOLOGICAL
Intervention: blood sample

Intervention type: BIOLOGICAL
Intervention: blood sample
Study: NCT02332707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir
Description: Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: One EBR 50 mg tablet (Part A), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: One EBR 50 mg tablet (Part A), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: One EBR 50 mg tablet (Part A), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: One EBR 50 mg tablet (Part A), taken q.d. by mouth.
Study: NCT04349592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg tablet oral, one tablet three times a day for 7 days
Study: NCT02828670

Intervention type: PROCEDURE
Intervention: spleen sample

Intervention type: PROCEDURE
Intervention: spleen sample
Study: NCT03011944

Intervention type: OTHER
Intervention: Quality Improvement Program
Description: Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
Study: NCT02224196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual ventilation
Description: Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pressure-controlled ventilation
Description: Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
Study: NCT03035487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided prostate exam using SOC ultrasound system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mpMRI guided prostate examination using PI-RADS v2
Description: mpMRI guided prostate examination using standard of care MRI system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution micro-ultrasound guided prostate biopsy
Study: NCT01656356

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avian Flu Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04732013

Intervention type: OTHER
Intervention: No clinical intervention is planned; study is observational
Description: No intervention
Study: NCT03359018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
Study: NCT02324634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroTrac Rehab dual channel device
Description: ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
Study: NCT03908489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vital pulpotomy primary molars using garlic oil
Description: vital pulpotomy using garlic oil

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vital pulpotomy using mta
Description: mta vital pulpotomy
Study: NCT02382484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A dual chamber pacing system (BackBeat Medical)
Description: For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
Study: NCT02105753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1210nm Diode Laser treatments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1210nm Diode Laser treatments
Study: NCT04668027

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: impulse oscillation（IOS）
Description: The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchial provocation test(BPT)
Description: Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchial dilation test(BDT)
Description: The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
Study: NCT01588756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AcSDKP-NH2 inuline
Description: Once intravenous administration of 100 µg or less

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AcSDKP-NH2 Cr-EDTA
Description: Once intravenous administration of 100 µg or less
Study: NCT00732836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI Abraxane
Description: Escalating doses (beginning dose 180 mg/m\^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
Study: NCT05421000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WALANT
Description: Wide awake local anesthesia without tourniquet for distal radius fracture surgery
Study: NCT00732836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAI Abraxane
Description: Escalating doses (beginning dose 180 mg/m\^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Artery Catheter
Description: On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Artery Catheter
Description: On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Abraxane
Description: Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m\^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
Study: NCT01827683

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperbaric oxygen
Description: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen
Description: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
Study: NCT04094415

Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
Study: NCT04241978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PtDA)
Description: Patient Decision Aid (PtDA) are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
Study: NCT05421000

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locoregional anesthesia and tourniquet
Description: Locoregional anesthesia and tourniquet for distal radius fracture surgery
Study: NCT01431183

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mailed influenza vaccination reminder notice
Description: Influenza vaccination reminder sent by postal mail
Study: NCT02088385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemospray

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Conventional Technique
Study: NCT02266173

Intervention type: DRUG
Intervention: Pertuzumab
Description: Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
Study: NCT02594488

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Reveal LINQ implantable cardiac monitor
Description: The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
Study: NCT02953808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: 200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: 200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: 200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2315698
Description: 200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
Study: NCT00686556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg